Crystec Pharma

Activities: Ingredients Research & Development Pharmaceutical

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Distribution

Manufacturing Chemist LIVE 2022 in review (part II)

Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond
Research & Development

CrystecPharma and Biosidus collaborate on biotherapeutics

The first programme in the cooperation will develop a dry powder preparation of teriparatide for the treatment of osteoporosis
Research & Development

CrystecPharma to help develop inhaled formulation for respiratory conditions

SignalRx's SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor with a synergistic action on two pathways associated with the development of lung cancer and idiopathic pulmonary fibrosis
Finance

Crystec launch R&D centre in Jiangsu province, China

The Haimen facility will support the company’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology
Manufacturing

Crystec wins Contract Services and Outsourcing Award at CPhI Awards

Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing
Media

Major progress in next generation medicine initiative

Juniper Pharma Services has reached a key milestone in its work with CrystecPharma and the Advanced Manufacturing Supply Chain Initiative (AMSCI) to create a new platform to accelerate drug development
Manufacturing

New video from Crystec highlights mSAS technology

mSAS particle engineering versus conventional micronisation
Subscribe now